川芎嗪防治冠心病经皮冠状动脉介入术后再狭窄的临床研究

目的　探讨中药川芎嗪防治经皮冠状动脉介入术 (PCI)后再狭窄的作用。方法　对 16 5例首次接受 PCI治疗的冠心病 (CAD)患者随机分为服用川芎嗪组和对照组。观察两组临床症状、心功能 (NYHA)状况并复查心电图、超声心动图和检验指标 ,部分病例行冠状动脉造影复查。术后随访 6～ 12个月。结果　术前和术中两组在冠心病危险因素、病变特点和手术参数等方面无显著差异 (P>0 .0 5 )。经 6～ 12个月随访 ,川芎嗪组再狭窄发生率(4 1.6 7% )明显低于对照组 (76 .19% ) ,P<0 .0 5。两组患者均未见服药不良影响。结论　川芎嗪具有防治 PCI术后再狭窄的良好临床效果 ,本研究为我国传统中药应用于 PCI术后再狭窄开辟了一条中西医结合的道路。

Clinical effects of tetramethyl pyrazine on preventing restenosis after percutaneous coronary intervention

Objective To investigate the effects of tetramethyl pyrazine on restenosis after percutaneous coronary intervention (PCI). Methods 165 patients were randomly divided into 2 groups. During 6~12months follow-up, the results of the clinical characteristics, changes of ECG, echocardioghraphy, heart function (NYHA) and coronary angiography were compared between 2 groups. Results There was not obvious difference of clinical characteristics before PCI, coronary lesions and procedural parameters during PCI between 2 groups (P>0.05). Incidence of restenosis after PCI was significantly less in tetrametyl pyrazine group (41.67%) than that in control group (76.19%, P<0.05). No severe adverse effect was found. Conclusion These findings suggest that strategy of orally tetramethyl pyrazine is effective in prevention of restenosis after PCI.